Kurian, M., Nimgaonkar, V., Elghawy, O., Mamtani, R. (2025). Real-world enfortumab vedotin +/- pembrolizumab (EV+/-P)–based treatment toxicity, treatment discontinuation, and associations with survival in advanced urothelial carcinoma (aUC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.4562